Send to

Choose Destination
Semin Oncol. 1999 Feb;26(1 Suppl 5):1-5.

Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.

Author information

Department of Medicine, Royal Marsden Hospital, London, UK.


The final results of two very important randomized trials of irinotecan (Campto, Rhône-Poulenc Rorer, Antony, France) as second-line treatment for patients with advanced colorectal cancer are presented. In one trial, the new topoisomerase inhibitor was compared with best supportive care; in the other, its use was compared with the strategy of high-dose 5-fluorouracil (5-FU) infusion. In both trials, patients randomized to irinotecan experienced superior survival. In the comparison against best supportive care, patients treated with irinotecan also had a significantly superior quality of life. In the comparison with infusional 5-FU, the more effective antitumor activity of irinotecan may have helped maintain quality of life. These results have implications for clinical practice: following failure on 5-FU, irinotecan must now be considered the best available option for treatment.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center